ROCKET PHARMACEUTICALS INC
For the period ended Sep 30, 2024. Filed Nov 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 7, 2024
RCKT$2.39-2.1%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Summary of Abbreviated Terms
Rocket Pharmaceuticals, Inc. may be referred to as Rocket, the Company, we, our or us, in this Quarterly Report, unless the context otherwise indicates. Throughout this Quarterly Report, we have used terms which are defined below:
| AAV | Adeno-associated virus |
|---|---|
| ACM | Arrhythmogenic cardiomyopathy |
| ASC | Accounting Standard Codification |
| ASGCT | American Society of Gene & Cell Therapy |
| BLA | Biologics License Application |
| BNP | Brain natriuretic peptide |
| cGMP | Current Good Manufacturing Practice |
| CIEMAT | Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas |
| CIRM | California Institute for Regenerative Medicine |
| CMC | Chemistry Manufacturing Controls |
| CRL | Complete Response Letter |
| Cowen | Cowen and Company, LLC |
| CTIS | Clinical Trials Information Systems |
| DCM | Dilated Cardiomyopathy |
| DD | Danon Disease |
| DNA | Deoxyrubonucleic acid |
| EMA | European Medicines Agency |
| EU | European Union |
| Europe | EU |
| ESGCT | European Society of Gene & Cell Therapy |
| FA | Fanconi Anemia |
| FASB | Financial Accounting Standards Board |
| FDA | U.S. Food and Drug Administration |
| GOSH | Great Ormond Street Hospital |
| HNJ | Hospital Infantil de Nino Jesus |
| ICD | Implantable cardiac defibrillator |
| IND | Investigational New Drug application |
| IPR&D | In process research and development |
| KCCQ | Kansas City Cardiovascular Questionnaire |
| LAD-I | Leukocyte Adhesion Deficiency-I |
| LV | Lentiviral vector |
| MAA | Marketing Authorization Application |
| MHRA | Medicines and Healthcare Products Regulatory Agency |
| NYHA | New York Heart Association |
| PKD | Pyruvate Kinase Deficiency |
| PKP2-ACM | Plakophilin-2 Arrhythmogenic Cardiomyopathy |
| PRIME | Priority Medicines |
| PSU | Performance stock unit |
| R&D | Research and development |
| Renovacor | Renovacor, Inc. acquired by Rocket on December 1, 2022 |
| RMAT | Regenerative Medicine Advanced Therapy |
| RSU | Restricted stock unit |
| RTW | RTW Investments, L.P |
| SEC | Securities and Exchange Commission |
| Stanford | Center for Definitive and Curative Medicine at Stanford University School of Medicine |
| U.S. | United States |
| U.S. GAAP | U.S. Generally Accepted Accounting Principles |
| UCLA | University of California, Los Angeles |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.